Core Viewpoint - The company demonstrates strong confidence in its intrinsic value and long-term development through frequent share buybacks, signaling positive financial health and operational capabilities [1][2]. Group 1: Share Buyback Activity - The company has conducted its 10th share buyback announcement this month, repurchasing 190,000 shares at a price of HKD 5.13 per share, totaling approximately HKD 1 million [1]. - Cumulatively, the company has repurchased 3.34 million shares in December, amounting to around HKD 17 million [1]. - Frequent and sustained buyback operations reflect the company's belief that its current stock price is undervalued [2]. Group 2: Business Development and Industry Engagement - The company has joined the Health Sustainable Development Working Committee under the Shanghai Cooperation Organization's economic platform, enhancing its role in international healthcare collaboration and innovation [1]. - The company has surpassed 3 million participants in the "Beijing Universal Health Insurance" program for 2026, showcasing its strong operational capabilities and market recognition in the health insurance sector [1]. - The company has been elected as the vice-chair unit of the Smart Healthcare Working Committee of the China Internet Association, further solidifying its industry influence and technological leadership [1]. Group 3: Financial Performance - The company reported steady revenue growth in its mid-term results for the 2026 fiscal year, nearing breakeven [1]. - Significant improvement in key financial metrics is attributed to the continuous increase in gross margin of core business and enhanced operational efficiency [1]. - The company's improved financial health reflects its strengthened commercialization capabilities and substantial progress in operational quality [1].
医渡科技12月以来10次回购，斥资约1700万港元